Please use this identifier to cite or link to this item:
Title: Ovarian cancer and body size: Individual participant meta-analysis including 25,157 women with ovarian cancer from 47 epidemiological studies
Authors: V. Beral
C. Hermon
R. Peto
G. Reeves
L. Brinton
P. Marchbanks
E. Negri
R. B. Ness
P. H.M. Peeters
M. Vessey
E. E. Calle
S. M. Gapstur
A. V. Patel
L. Dal Maso
R. Talamini
A. Chetrit
G. Hirsh-Yechezkel
F. Lubin
S. Sadetzki
N. Allen
D. Bull
K. Callaghan
B. Crossley
K. Gaitskell
A. Goodill
J. Green
T. Key
K. Moser
R. Collins
R. Doll
C. A. Gonzalez
N. Lee
H. W. Ory
H. B. Peterson
P. A. Wingo
N. Martin
T. Pardthaisong
S. Silpisornkosol
C. Theetranont
B. Boosiri
S. Chutivongse
P. Jimakorn
P. Virutamasen
C. Wongsrichanalai
A. Tjonneland
L. Titus-Ernstoff
T. Byers
T. Rohan
B. J. Mosgaard
D. Yeates
J. L. Freudenheim
J. Chang-Claude
R. Kaaks
K. E. Anderson
A. Folsom
M. A. Rossing
D. B. Thomas
N. S. Weiss
E. Riboli
F. Clavel-Chapelon
D. Cramer
K. Robien
S. S. Tworoger
D. Cramer
S. E. Hankinson
S. S. Tworoger
S. Franceschi
C. La Vecchia
C. Magnusson
T. Riman
E. Weiderpass
A. Wolk
L. J. Schouten
P. A. Van den Brandt
N. Chantarakul
S. Koetsawang
D. Rachawat
D. Palli
A. Black
A. Berrington de Gonzalez
D. M. Freedman
P. Hartge
A. W. Hsing
J. V. Lacey
R. N. Hoover
C. Schairer
S. Graff-Iversen
R. Selmer
C. J. Bain
A. C. Green
D. M. Purdie
V. Siskind
P. M. Webb
American Cancer Society
IRCCS Centro Di Riferimento Oncologico Aviano
The Gertner Institute
Cancer Epidemiology Unit
Clinical Trial Service Unit
Institute Catala Oncologia
Centers for Disease Control and Prevention
Chiang Mai University
Chulalongkorn University
Institute of Cancer Epidemiology - Denmark
Geisel School of Medicine at Dartmouth
Colorado School of Public Health
Albert Einstein College of Medicine of Yeshiva University
Amtssygehuset i Herlev
Department of Public Health
University at Buffalo, State University of New York
German Cancer Research Center
University of Minnesota School of Public Health
University of Washington, Seattle
Imperial College London
Centre de recherche en epidemiologie et sante des populations
Harvard Medical School
Brigham and Women's Hospital
Channing Laboratory
International Agency for Research on Cancer
Universita degli Studi di Milano
Karolinska Institutet
Maastricht University
Mahidol University
Centro Per Lo Studio E La Prevenzione Oncologica
National Cancer Institute
Norwegian Institute of Public Health
Queensland Institute of Medical Research
Roswell Park Cancer Institute
Royal College of General Practitioners' Oral Contraception Study
Curtin University
University of Texas System
University of Massachusetts System
Boston University
Stanford University
University of Athens Medical School
Universidad de Chile
University of Hawaii System
Skånes universitetssjukhus
University of Pennsylvania
University Medical Center Utrecht
University of Southern California
University of Toronto
Universitetet i Tromso
George Washington University
Vanderbilt University
Organisation Mondiale de la Sante
Yale University
Keywords: Medicine
Issue Date: 1-Apr-2012
Citation: PLoS Medicine. Vol.9, No.4 (2012)
Abstract: Background: Only about half the studies that have collected information on the relevance of women's height and body mass index to their risk of developing ovarian cancer have published their results, and findings are inconsistent. Here, we bring together the worldwide evidence, published and unpublished, and describe these relationships. Methods and Findings: Individual data on 25,157 women with ovarian cancer and 81,311 women without ovarian cancer from 47 epidemiological studies were collected, checked, and analysed centrally. Adjusted relative risks of ovarian cancer were calculated, by height and by body mass index. Ovarian cancer risk increased significantly with height and with body mass index, except in studies using hospital controls. For other study designs, the relative risk of ovarian cancer per 5 cm increase in height was 1.07 (95% confidence interval [CI], 1.05-1.09; p < 0.001); this relationship did not vary significantly by women's age, year of birth, education, age at menarche, parity, menopausal status, smoking, alcohol consumption, having had a hysterectomy, having first degree relatives with ovarian or breast cancer, use of oral contraceptives, or use of menopausal hormone therapy. For body mass index, there was significant heterogeneity (p < 0.001) in the findings between ever-users and never-users of menopausal hormone therapy, but not by the 11 other factors listed above. The relative risk for ovarian cancer per 5 kg/m 2 increase in body mass index was 1.10 (95% CI, 1.07-1.13; p < 0.001) in never-users and 0.95 (95% CI, 0.92-0.99; p = 0.02) in ever-users of hormone therapy. Conclusions: Ovarian cancer is associated with height and, among never-users of hormone therapy, with body mass index. In high-income countries, both height and body mass index have been increasing in birth cohorts now developing the disease. If all other relevant factors had remained constant, then these increases in height and weight would be associated with a 3% increase in ovarian cancer incidence per decade. © 2012 Collaborative Group on Epidemiological Studies of Ovarian Cancer.
ISSN: 15491676
Appears in Collections:Scopus 2011-2015

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.